$119.26
0.72% yesterday
Nasdaq, Nov 20, 10:08 pm CET

Illumina Stock price

$119.26
+19.76 19.86% 1M
+35.05 41.62% 6M
-14.37 10.75% YTD
-12.42 9.43% 1Y
-99.39 45.46% 3Y
-173.81 59.31% 5Y
-50.60 29.79% 10Y
+111.25 1,388.22% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.86 0.72%

New AI Insights on Illumina Insights AI Insights on Illumina

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
$18.2b
Enterprise Value
$18.9b
Net debt
$714.0m
Cash
$1.3b
Shares outstanding
153.0m
Valuation (TTM | estimate)
P/E
26.2 | 25.2
P/S
4.2 | 4.2
EV/Sales
4.4 | 4.3
EV/FCF
18.9
P/B
7.7
Financial Health
Equity Ratio
37.7%
Return on Equity
-51.5%
ROCE
20.8%
ROIC
15.8%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$4.3b | $4.4b
EBITDA
$1.2b | $1.2b
EBIT
$875.0m | $961.9m
Net Income
$703.0m | $725.3m
Free Cash Flow
$1.0b
Growth (TTM | estimate)
Revenue
-2.3% | -0.2%
EBITDA
233.3% | 76.1%
EBIT
154.4% | 45.5%
Net Income
144.4% | 159.3%
Free Cash Flow
82.8%
Margin (TTM | estimate)
Gross
66.7%
EBITDA
26.8% | 26.8%
EBIT
20.4%
Net
16.4% | 16.6%
Free Cash Flow
23.3%
More
EPS
$4.6
FCF per Share
$6.5
Short interest
6.9%
Employees
9k
Rev per Employee
$490.0k
Show more

Is Illumina a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Illumina Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Illumina forecast:

14x Buy
50%
11x Hold
39%
3x Sell
11%

Analyst Opinions

28 Analysts have issued a Illumina forecast:

Buy
50%
Hold
39%
Sell
11%

Financial data from Illumina

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,288 4,288
2% 2%
100%
- Direct Costs 1,426 1,426
10% 10%
33%
2,862 2,862
2% 2%
67%
- Selling and Administrative Expenses 1,019 1,019
16% 16%
24%
- Research and Development Expense 968 968
22% 22%
23%
1,150 1,150
233% 233%
27%
- Depreciation and Amortization 275 275
27,400% 27,400%
6%
EBIT (Operating Income) EBIT 875 875
154% 154%
20%
Net Profit 703 703
144% 144%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Illumina directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Illumina Stock News

Neutral
Seeking Alpha
one day ago
Illumina, Inc. ( ILMN ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC Okay. Good morning, everybody.
Neutral
PRNewsWire
9 days ago
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO , Nov. 12, 2025 /PRNews...
Neutral
PRNewsWire
9 days ago
SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Wolfe Research Healthcare Conference 2025 on November 19, 2025 Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A ...
More Illumina News

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Jacob Thaysen
Employees 9,000
Founded 1998
Website www.illumina.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today